Compositions and methods of metal-containing materials

• US 20040191329A1
• Filed: 10/22/2003
• Published: 09/30/2004
• Est. Priority Date: 07/27/2000
• Status: Abandoned Application

• Current Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Original Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Inventors: Naylor, Antony G., Lam, Kan, Wright, John B., Gillis, Scott H., Schechter, Paul, Burrell, Robert E., Moxham, Peter H., Yin, Hua Qing, Robert Stiles, James Alexander
• Application Number:
  US10/690,715
• Publication Number:
  US 20040191329A1
• Time in Patent Office: Days
• US Class Current: 424/618
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 2800/413 Nanosized, i.e. having sizes below 100 nm
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/242 Gold; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 33/244 Lanthanides; Compounds thereof medicinal preparations containing radioactive lanthanides for use in therapy or testing in vivo A61K51/00
• CPC Class Codes: A61K 33/38 Silver; Compounds thereof
• CPC Class Codes: A61K 8/19 containing inorganic ingredients
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61L 15/46 Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
• CPC Class Codes: A61L 17/145 Coating
• CPC Class Codes: A61L 2300/104 Silver, e.g. silver sulfadiazine
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 27/30 Inorganic materials
• CPC Class Codes: A61L 29/10 : Inorganic materials
• CPC Class Codes: A61L 31/082 : Inorganic materials
• CPC Class Codes: A61Q 17/005 : Antimicrobial preparations
• CPC Class Codes: A61Q 19/00 : Preparations for care of the skin
• CPC Class Codes: B82Y 5/00 : Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Compositions and methods of metal-containing materials of metal-containing materials are disclosed. The metal-containing material can be, for example, an antimicrobial material, an anti-biofilm material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, anti-proliferative, MMP modulating material, an atomically disordered, crystalline material, and/or a nanocrystalline material. In certain embodiments, the metal-containing material is an atomically disordered, nanocrystalline silver-containing material.

Claims

1. A pharmaceutical composition, comprising:

a pharmaceutically acceptable carrier; and

a silver-containing material in the pharmaceutically acceptable carrier,

wherein the pharmaceutical composition comprises from about 0.001 weight percent to about 50 weight percent of the silver-containing material.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about 0.1 weight percent of the silver-containing material.

3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about 0.5 weight percent of the silver-containing material.

4. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises less than about 40 weight percent of the silver-containing material.

5. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises less than about 30 weight percent of the silver-containing material.

6. The pharmaceutical composition of claim 1, wherein the silver-containing material is selected from the group consisting of colloidal silver, silver nitrate and silver sulfadiazine, silver carbonate, silver acetate, silver lactate, silver citrate, silver oxide, silver hydroxide, silver succinate, silver chlorate, alkali silver thiosulphates, silver myristate, silver sorbate, silver stearate, silver oleate, silver glutonate, silver adipate, atomically disordered silver, nanocrystalline silver and combinations thereof.

7. A method of treating a subject having a condition, comprising:

contacting an area of the subject having the condition with a pharmaceutical composition, the pharmaceutical composition comprising;

a pharmaceutically acceptable carrier; and

a silver-containing material in the pharmaceutically acceptable carrier,

wherein the pharmaceutical composition comprises from about 0.001 weight percent to about 50 weight percent of the silver-containing material.

8. The method of claim 7, wherein the pharmaceutical composition comprises at least about 0.1 weight percent of the silver-containing material.

9. The method of claim 7, wherein the pharmaceutical composition comprises at least about 0.5 weight percent of the silver-containing material.

10. The method of claim 7, wherein the pharmaceutical composition comprises less than about 40 weight percent of the silver-containing material.

11. The method of claim 7, wherein the pharmaceutical composition comprises less than about 30 weight percent of the silver-containing material.

12. The method of claim 7, wherein the silver-containing material is selected from the group consisting of colloidal silver, silver nitrate and silver sulfadiazine, silver carbonate, silver acetate, silver lactate, silver citrate, silver oxide, silver hydroxide, silver succinate, silver chlorate, alkali silver thiosulphates, silver myristate, silver sorbate, silver stearate, silver oleate, silver glutonate, silver adipate, atomically disordered silver, nanocrystalline silver and combinations thereof.

13. The method of claim 7, bacterial conditions, biofilm conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, hyperproliferative conditions, noncancerous growths and cancerous conditions.

14. The method of claim 7, wherein the condition comprises a skin condition.

15. A method of treating a subject having a respiratory condition, comprising:

contacting an area of the subject having the respiratory condition with a silver-containing material.

16. The method of claim 15, wherein the respiratory condition is selected from the group consisting of bacterial conditions, biofilm conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths, hyperproliferative conditions, cancerous conditions and combinations thereof.

17. The method of claim 15, wherein the condition is selected from the group consisting of asthma, emphysema, bronchitis, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, fibrotic conditions, pulmonary atelectasis, tuberculosis, pneumonia, sinusitis, allergic rhinitis, pharyngitis, mucositis, stomatitis, chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis and combinations thereof.

18. The method of claim 15, wherein the silver-containing material is selected from the group consisting of colloidal silver, silver nitrate and silver sulfadiazine, silver carbonate, silver acetate, silver lactate, silver citrate, silver oxide, silver hydroxide, silver succinate, silver chlorate, alkali silver thiosulphates, silver myristate, silver sorbate, silver stearate, silver oleate, silver glutonate, silver adipate, atomically disordered silver, nanocrystalline silver and combinations thereof.

19. The method of claim 15, wherein, when contacted with the area of the subject having the respiratory condition, the silver-containing material is in a solution, in an aerosol, in a pharmaceutically acceptable carrier, or in the form of a free-standing powder.

20. The method of claim 15, wherein the area of the subject is selected from the group consisting of the subject'"'"'s oral cavity, the subject'"'"'s nasal cavity, the subject'"'"'s lungs and combinations thereof.

21. The method of claim 15, wherein, when contacted with the area of the subject having the respiratory condition, the silver-containing material is in a solution, and the solution contains at most about 0.5 weight percent of the silver-containing material.

22. The method of claim 15, wherein, when contacted with the area of the subject having the respiratory condition, the silver-containing material is the form of a dry powder aerosol, and the dry powder aerosol contains at most about 99 weight percent of the silver-containing material.

23. The method of claim 22, wherein the dry powder aerosol contains at least about 10 weight percent of the silver-containing material.

24. A method of treating a subject having a condition, comprising:

contacting an area of the subject having the condition with a silver-containing material by injecting a free-standing powder of the silver-containing material into the subject, or by inhaling a free-standing powder of the silver-containing material,

wherein the silver-containing material is selected from the group consisting of colloidal silver, silver nitrate and silver sulfadiazine, silver carbonate, silver acetate, silver lactate, silver citrate, silver oxide, silver hydroxide, silver succinate, silver chlorate, alkali silver thiosulphates, silver myristate, silver sorbate, silver stearate, silver oleate, silver glutonate, silver adipate, atomically disordered silver, nanocrystalline silver and combinations thereof.

25. The method of claim 24, wherein the condition is selected from the group consisting of wherein the condition is selected from the group consisting of bacterial conditions, biofilm conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, hyperproliferative conditions, noncancerous growths, cancerous conditions and combinations thereof.

26. The method of claim 24, wherein the condition is selected from skin conditions, integument conditions, respiratory conditions, musculo-skeletal conditions, circulatory conditions, mucosal conditions, serosal conditions and combinations thereof.

27. The method of claim 24, wherein the free-standing powder has an average particle size of about 10 microns or less.

28. A free-standing powder of a silver-containing material,

wherein the silver-containing material is selected from the group consisting of colloidal silver, silver nitrate and silver sulfadiazine, silver carbonate, silver acetate, silver lactate, silver citrate, silver oxide, silver hydroxide, silver succinate, silver chlorate, alkali silver thiosulphates, silver myristate, silver sorbate, silver stearate, silver oleate, silver glutonate, silver adipate, atomically disordered silver, nanocrystalline silver and combinations thereof.

29. The method of claim 28, wherein the free-standing powder has an average particle size of about 10 microns or less.

30. An aerosol comprising a silver-containing material, wherein the silver-containing material is selected from the group consisting of colloidal silver, silver nitrate and silver sulfadiazine, silver carbonate, silver acetate, silver lactate, silver citrate, silver oxide, silver hydroxide, silver succinate, silver chlorate, alkali silver thiosulphates, silver myristate, silver sorbate, silver stearate, silver oleate, silver glutonate, silver adipate, atomically disordered silver, nanocrystalline silver and combinations thereof.

31. The aerosol of claim 30, wherein the aerosol further comprises a solvent or the silver-containing material.

32. The aerosol of claim 31, wherein the aerosol comprises at most about 99 weight percent of the silver-containing material.

33. The aerosol of claim 30, wherein the aerosol comprises at most about 99 weight percent of the silver-containing material.